{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:28:20Z","timestamp":1794580100712,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.17269\/s41997-026-01178-x","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:35:15Z","timestamp":1773941715000},"page":"1105-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution"],"prefix":"10.17269","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9362-0178","authenticated-orcid":false,"given":"Jenna","family":"Matsukubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2534","authenticated-orcid":false,"given":"Erik Loewen","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-3232","authenticated-orcid":false,"given":"Rachael","family":"MacDonald-Spracklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Iseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2057-4071","authenticated-orcid":false,"given":"Jess G.","family":"Fiedorowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-4030","authenticated-orcid":false,"given":"Benedikt","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-300X","authenticated-orcid":false,"given":"Daniel T.","family":"Myran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"6","key":"1178_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/jamapsychiatry.2023.0549","volume":"80","author":"JS Aday","year":"2023","unstructured":"Aday, J. S., Carhart-Harris, R. L., & Woolley, J. D. (2023). Emerging challenges for psychedelic therapy. JAMA Psychiatry, 80(6), 533\u2013534. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.0549","journal-title":"JAMA Psychiatry"},{"key":"1178_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/add.16575","author":"CM Andrews","year":"2024","unstructured":"Andrews, C. M., Hall, W., Humphreys, K., & Marsden, J. (2024). Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis? Addiction. https:\/\/doi.org\/10.1111\/add.16575","journal-title":"Addiction"},{"issue":"10","key":"1178_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O\u2019Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953\u2013962. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096","journal-title":"JAMA Psychiatry"},{"key":"1178_CR4","unstructured":"Canadian Public Health Association. (2023). Forum on a public health approach to psychedelics: Summary report [PDF]. Retrieved September 6, 2025, from https:\/\/www.cpha.ca\/sites\/default\/files\/uploads\/policy\/psychedelics-forum\/2023-psychedelics-forum-report.pdf"},{"key":"1178_CR5","unstructured":"CBC News. (n.d.). Shroom boom. CBC News. Retrieved September 19, 2025, from https:\/\/www.cbc.ca\/newsinteractives\/features\/magic-mushroom-medicine"},{"key":"1178_CR6","unstructured":"Dictionary, Census of population, 2021 \u2013 Census metropolitan area (CMA) and census agglomeration (CA). (n.d.). Retrieved September 6, 2025, from https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/ref\/dict\/az\/definition-eng.cfm?ID=geo009"},{"key":"1178_CR7","unstructured":"Dictionary, Census of population, 2021 \u2013 Dissemination area (DA). (n.d.). Retrieved September 6, 2025, from https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/ref\/dict\/az\/definition-eng.cfm?ID=geo021"},{"key":"1178_CR8","doi-asserted-by":"publisher","unstructured":"Goodman, S., Leos-Toro, C., & Hammond, D. (2019). The impact of plain packaging and health warnings on consumer appeal of cannabis products. Drug and Alcohol Dependence, 205. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107633","DOI":"10.1016\/j.drugalcdep.2019.107633"},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","volume":"327","author":"GM Goodwin","year":"2023","unstructured":"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., P\u00e1len\u00ed\u010dek, T., Redjep, O., Repantis, D., & Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120\u2013127. https:\/\/doi.org\/10.1016\/j.jad.2023.01.108","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"1178_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/J.JEMERMED.2022.12.025","volume":"64","author":"B Hammig","year":"2023","unstructured":"Hammig, B., Jones, C., & Haldeman, S. (2023). Pediatric poisonings associated with ingestion of marijuana products. The Journal of Emergency Medicine, 64(2), 181\u2013185. https:\/\/doi.org\/10.1016\/J.JEMERMED.2022.12.025","journal-title":"The Journal of Emergency Medicine"},{"key":"1178_CR11","unstructured":"Health Canada. (n.d.). Canadian Alcohol and Drugs Survey (CADS): Summary of results for 2023. Government of Canada. Retrieved September 6, 2025, from https:\/\/www.canada.ca\/en\/health-canada\/services\/canadian-alcohol-drugs-survey\/2023-summary.html"},{"key":"1178_CR12","unstructured":"Health Canada. (2019). Canadian Alcohol and Drugs Survey (CADS): 2019 detailed tables. Government of Canada. Retrieved September, 6, 2025, from https:\/\/www.canada.ca\/en\/health-canada\/services\/canadian-alcohol-drugs-survey\/2019-summary\/detailed-tables.html"},{"key":"1178_CR13","unstructured":"Health Canada. (2023). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. Government of Canada. Retrieved September 6, 2025, from https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/announcements\/requests-special-access-program-psychedelic-assisted-psychotherapy.html"},{"issue":"7","key":"1178_CR14","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs, T. S., & Johansen, P\u00d8r. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253","journal-title":"Journal of Psychopharmacology"},{"key":"1178_CR15","doi-asserted-by":"publisher","unstructured":"Lee, J. G. L., D\u2019Angelo, H., Kuteh, J. D., & Martin, R. J. (2016). Identification of vape shops in two North Carolina counties: An approach for states without retailer licensing. International Journal of Environmental Research and Public Health, 13(11). https:\/\/doi.org\/10.3390\/ijerph13111050","DOI":"10.3390\/ijerph13111050"},{"issue":"15","key":"1178_CR16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1056\/nejme2102835","volume":"384","author":"JA Lieberman","year":"2021","unstructured":"Lieberman, J. A. (2021). Back to the future \u2014 The therapeutic potential of psychedelic drugs. The New England Journal of Medicine, 384(15), 1460\u20131461. https:\/\/doi.org\/10.1056\/nejme2102835","journal-title":"The New England Journal of Medicine"},{"key":"1178_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.addbeh.2018.12.001","volume":"90","author":"S Mahamad","year":"2019","unstructured":"Mahamad, S., & Hammond, D. (2019). Retail price and availability of illicit cannabis in Canada. Addictive Behaviors, 90, 402\u2013408. https:\/\/doi.org\/10.1016\/j.addbeh.2018.12.001","journal-title":"Addictive Behaviors"},{"key":"1178_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2853","author":"J Matsukubo","year":"2025","unstructured":"Matsukubo, J., Dickson, S., Xiao, J., Friesen, E. L., Solmi, M., Fiedorowicz, J. G., Fischer, B., & Myran, D. T. (2025). Psilocybin dispensaries and online health claims in Canada. JAMA Network Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.2853","journal-title":"JAMA Network Open"},{"issue":"5","key":"1178_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/dar.13650","volume":"42","author":"DT Myran","year":"2023","unstructured":"Myran, D. T., Friesen, E. L., Dickson, S., Konikoff, L., Arora, G., & Tanuseputro, P. (2023). Access to legal cannabis market in Canada over the four years following non-medical cannabis legalisation. Drug and Alcohol Review, 42(5), 1114\u20131119.","journal-title":"Drug and Alcohol Review"},{"key":"1178_CR20","doi-asserted-by":"publisher","unstructured":"Myran, D. T., Pugliese, M., Xiao, J., Kaster, T. S., Husain, ; M Ishrat, Anderson, K. K., Fabiano, N., Wong, S., Fiedorowicz, J. G., Webber, Colleen, Tanuseputro, P., & Solmi, M. (2024). Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3532","DOI":"10.1001\/jamapsychiatry.2024.3532"},{"issue":"12","key":"1178_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004805","volume":"22","author":"DT Myran","year":"2025","unstructured":"Myran, D. T., MacDonald-Spracklin, R., Pugliese, M., Gibb, M., Fiedorowicz, J. G., Kaster, T. S., & Solmi, M. (2025a). Hospital-based care for hallucinogens and risk of mania and bipolar disorder: A population-based cohort study. Plos Medicine, 22(12), Article e1004805.","journal-title":"Plos Medicine"},{"key":"1178_CR22","doi-asserted-by":"crossref","unstructured":"Myran, D. T., Pugliese, M., Xiao, J., Kaster, T. S., Husain, M. I., Anderson, K. K.,\u00a0..., & Solmi, M. (2025b). Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA psychiatry, 82(2), 142\u2013150.","DOI":"10.1001\/jamapsychiatry.2024.3532"},{"issue":"8","key":"1178_CR23","doi-asserted-by":"publisher","first-page":"E204","DOI":"10.1503\/cmaj.241191","volume":"197","author":"DT Myran","year":"2025","unstructured":"Myran, D. T., Xiao, J., Fabiano, N., Pugliese, M., Kaster, T. S., Rosenblat, J. D., Husain, I., Fiedorowicz, J. G., Wong, S., Tanuseputro, P., & Solmi, M. (2025c). Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population. CMAJ, 197(8), E204\u2013E213.","journal-title":"CMAJ"},{"issue":"2","key":"1178_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131\u2013181. https:\/\/doi.org\/10.1016\/j.pharmthera.2003.11.002","journal-title":"Pharmacology & Therapeutics"},{"key":"1178_CR25","doi-asserted-by":"publisher","unstructured":"Pearson, J. L., Borges, L., Darrow, L. A., Nippler, G., & Friedman, A. S. (2025). Development and evaluation of a method to compile a national list of cannabis dispensaries. Drug and Alcohol Dependence, 112964. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112964","DOI":"10.1016\/j.drugalcdep.2025.112964"},{"issue":"2","key":"1178_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.26828\/cannabis.2018.02.003","volume":"1","author":"E Pedersen","year":"2018","unstructured":"Pedersen, E., Zander-Cotugno, M., Shih, R., Tucker, J., Dunbar, M., & D\u2019Amico, E. (2018). Online methods for locating medical marijuana dispensaries: Practical considerations for future research. Cannabis, 1(2), 22\u201335. https:\/\/doi.org\/10.26828\/cannabis.2018.02.003","journal-title":"Cannabis"},{"key":"1178_CR27","unstructured":"Psilocybin and Psilocin (Magic Mushrooms) - Canada.ca. (n.d.). Retrieved September 6, 2025, from https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/controlled-illegal-drugs\/magic-mushrooms.html#a33"},{"issue":"10","key":"1178_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1177\/0269881120919957","volume":"34","author":"B Romeo","year":"2020","unstructured":"Romeo, B., Karila, L., Martelli, C., & Benyamina, A. (2020). Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of Psychopharmacology, 34(10), 1079\u20131085. https:\/\/doi.org\/10.1177\/0269881120919957","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"1178_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith, K. W., Sicignano, D. J., Hernandez, A. V., & White, C. M. (2022). MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta-analysis. Journal of Clinical Pharmacology, 62(4), 463\u2013471. https:\/\/doi.org\/10.1002\/jcph.1995","journal-title":"Journal of Clinical Pharmacology"},{"key":"1178_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","volume":"64","author":"M Solmi","year":"2022","unstructured":"Solmi, M., Chen, C., Daure, C., Buot, A., Ljuslin, M., Verroust, V., Mallet, L., Khazaal, Y., Rothen, S., Thorens, G., Zullino, D., Gobbi, G., Rosenblat, J., Husain, M. I., De Gregorio, D., Castle, D., & Sab\u00e9, M. (2022). A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology, 64, 44\u201360. https:\/\/doi.org\/10.1016\/j.euroneuro.2022.09.004","journal-title":"European Neuropsychopharmacology"},{"key":"1178_CR31","doi-asserted-by":"publisher","unstructured":"Zeifman, R. J., Yu, D., Singhal, N., Wang, G., Nayak, S. M., & Weissman, C. R. (2022). Corrigendum to Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials. In Journal of Clinical Psychiatry (Vol. 83, Issue 3). Physicians Postgraduate Press Inc. https:\/\/doi.org\/10.4088\/JCP.22L14505","DOI":"10.4088\/JCP.22L14505"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-026-01178-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-026-01178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:58:12Z","timestamp":1794578292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-026-01178-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.17269\/s41997-026-01178-x","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"value":"0008-4263","type":"print"},{"value":"1920-7476","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available data without identifying information; no ethics approval or informed consent was required.","order":1,"name":"Ethics","label":"Ethics approval and consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Solmi received honoraria and has been a consultant for Angelini, AbbVie, Bausch Health, Boehringer Ingelheim, Lundbeck, Otsuka, and Teva.\u00a0Fischer has held research and policy support grants and\/or contracts in the areas of substance use, health, crime from public funding and\/or government-related organizations (i.e., public-only sources) in the last three years, and\u00a0acknowledges present research and policy support from the Waypoint Centre for Mental Health Care\/Waypoint Research Institute and the University of the Fraser Valley. All remaining authors have no conflicts of interest relevant to this article to disclose.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}